Navigation Links
IBF/LifeScience Alley MedTech Investing Conference Adds Ashley Boam, Acting Deputy Director for Science and Review Policy, Office of Device Evaluation, Center for Devices and Radiological Health, FDA
Date:3/18/2008

Boam to address venture capitalists and venture-backed companies on the

present and future FDA regulation of medical devices

ST. LOUIS PARK, Minn., and Massapequa, N.Y., March 18 /PRNewswire/ -- Conference organizer International Business Forum (IBF) and LifeScience Alley, a Minneapolis trade association of medical device and other biotechnology firms, today announced that Ashley Boam, Acting Deputy Director for Science and Review Policy, Office of Device Evaluation at the Center for Devices and Radiological Health at FDA, will join the lineup of speakers at the 7th Annual MedTech Investing Conference (http://www.medtechconference.com) taking place at the Radisson Plaza Hotel in Minneapolis, Minnesota.

Boam will be interviewed by legal/regulatory firm DuVal & Associates President, Mark DuVal on the future of FDA's regulation of medical devices, clinical trials and approval requirements. They will discuss how FDA's changing requirements can impact the timeline to approval for medical devices and how that could impact the amount of investments in devices going forward.

This Fireside Chat is scheduled for 11:00 am on Thursday, May 14th, the second day of the conference. It will be the first time Ms. Boam presents at the MedTech Investing Conference which happens to be the premier event for medical device investors and entrepreneurs from around the nation.

To learn more about the event and to register, visit the newly launched website http://www.medtechconference.com.

About LifeScience Alley(TM)

LifeScience Alley(TM) is the largest trade association serving the life sciences in the Upper Midwest. It represents more than 570 member companies, organizations and institutions of all sizes that devote their efforts to the research, development and commercialization of the life sciences. LifeScie
'/>"/>

SOURCE International Business Forum
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
6. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Avicena Group to Present at Noble Financial Conference
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer 2Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer 3Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 33
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... Inc., a biomarker development and software company, has ... Reserve University. The deal has potential to enhance ... inflammatory diseases. Proteomics is the scientific next ... biological systems. NeoProteomics, founded in 2006 in Cleveland ...
... climate change and population growth on agricultural land area vary ... University of Illinois researchers. Regions with relative high latitudes ... significant increase in arable land in coming years, but Africa, ... Civil and environmental engineering professor Ximing Cai and graduate ...
... AURORA, Colo. (March 25, 2011) Researchers seeking to unravel ... smell have discovered a previously unknown step in how odors ... study, focusing on how mice respond to odors, showed that smells ... on the way to the brain then sent to the ...
Cached Biology News:Case Western Reserve and NeoProteomics announce exclusive option 2Study predicts large regional changes in farmland area 2Researchers unlock new secret to how smells are detected 2